Stocks TelegraphStocks Telegraph
Stock Ideas

BDX Company Profile and Key Details

NYSE : BDX

Becton Dickinson and

$149.42
-1.14-0.76%
Open: 10:08 AM
68.73
B+ESG ScoreESG Rating

Price Chart

Stock Price Today

Becton, Dickinson and Company (BDX) stock declined over -0.76%, trading at $149.42 on NYSE, down from the previous close of $150.56. The stock opened at $155.98, fluctuating between $148.23 and $155.98 in the recent session.

Stock Snapshot

150.56
Prev. Close
54.13B
Market Cap
148.23
Day Low
11.11
P/E Ratio
13.45
EPS (TTM)
9.13
Cash Flow per Share
155.98
Open
362.3M
Number of Shares
155.975
Day High
99.78%
Free Float in %
87.32
Book Value
136.81K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jul 08, 2026155.98156.29150.35150.562.28M
Jul 07, 2026158.00159.49156.26156.301.74M
Jul 06, 2026157.95158.01154.32155.541.46M
Jul 02, 2026154.94158.72153.93158.082.03M
Jul 01, 2026151.76154.04151.56152.902.06M
Jun 30, 2026155.02155.11149.69151.332.06M
Jun 29, 2026154.73155.25152.97155.192.36M
Jun 26, 2026152.80156.89151.63155.9211.7M
Jun 25, 2026148.42152.83147.20151.382.44M
Jun 24, 2026145.66149.20144.61147.772.06M
Jun 23, 2026142.55145.59141.25143.922.8M
Jun 22, 2026142.44143.43140.11140.713.38M
Jun 18, 2026142.02144.70141.75143.986.08M
Jun 17, 2026144.50145.60140.63141.612.72M
Jun 16, 2026146.57146.89144.26145.161.51M
Jun 15, 2026146.60147.94145.44145.521.76M
Jun 12, 2026147.94149.00144.40146.241.96M
Jun 11, 2026147.33148.09145.90147.351.64M
Jun 10, 2026151.48151.62147.74147.791.72M
Jun 09, 2026149.72152.55148.70152.042.21M

Contact Details

Franklin Lakes, NJ 07417-1880

United States

https://www.bd.com201 847 6800

About Company

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Company Information

Employees70000
Beta0.28
Sales or Revenue$21.84B
5Y Sales Change%0.322%
Fiscal Year EndsSeptember
SectorHealthcare
IndustryMedical - Instruments & Supplies

Company Overview

Becton, Dickinson and Company (NYSE:BDX) closed at $150.56 USD, losing -$5.74 (-3.67%) from the previous close of $156.30. The stock is currently mid-range between its 52-week high and low $127.59 and $187.35. With a market capitalization of about $54.55 billion, Becton, Dickinson and Company is classified as a large-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 3.00 million shares, volume is running light vs its 52-week average. Headquartered in Franklin Lakes, NJ, Becton, Dickinson and Company operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Thomas E. Polen Jr., the company employs approximately 70,000 people and listed since February 21, 1973. Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 2.38%, SMA50 8.01%, SMA200 18.36%). The stock’s 14-day RSI is 57.35 (neutral), while the ATR of 4.77 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -5.71% below its high and over 38.52% above its low. Average 10-day trading volume of 2.00 million shares is below the 3-month average of 2.95 million, indicating normal recent market interest.

Valuation Metrics

Becton, Dickinson and Company trades at a P/E ratio of 38.18, slightly above the S&P 500 average, with a price-to-sales ratio of 2.56 and a price-to-book ratio of 1.75 suggesting the stock is closer to book value. The P/FCF stands at 17.39, also above market averages.

Dividend & Fair Value

Becton, Dickinson and Company last paid a dividend of 3.74 per share, this equals a trailing yield of roughly 1.62%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $668.55. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Becton, Dickinson and Company generated EPS of $6.12 over the past year. Five-year average earnings growth is 16.45%. Wall Street analysts project EPS growth of 8.09% annually over the next five years. The latest quarter delivered EPS of $2.90. The next quarter is forecast at $2.78. Next year's EPS is expected at $11.12. Analyst sentiment is neutral. Analyst rating data shows there are 5 Strong Buy ratings, 5 Buy ratings, 17 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $233.00 to $159.00. The high target offers 54.76% upside. The low target suggests 5.61% downside. The mean target is $197.48. This offers 31.16% upside. Becton, Dickinson and Company earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 4.32%. The prior quarter beat by 31.67%. Over the last six quarters, Apple has recorded several small beats. These include 14.33% in February 05, 2025.

Shareholding & Insider Activity

Becton, Dickinson and Company has 275.54 million shares outstanding. The public float is 274.74 million shares, elevated short interest at 2.98% of float. This equals 7.20 million shares. The short ratio is 2.14 days. Institutional investors hold 92.78% of the float. Insiders own 0.57%. FORLENZA VINCENT A holds 208.86 thousand shares, Polen Thomas E Jr has 110.16 thousand shares and RING TIMOTHY M has 93.69 thousand shares. Over the past six months, insider transactions show net selling. They sold 7.38 thousand shares across 11 transactions.

Price Forecast & Outlook

Our AI price prediction model suggests that Becton, Dickinson and Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.65%, with price expected at $163.59 by July 22, 2026, within a range of $159.90 to $166.90 3-Month Outlook: Projected rise of 41.03%, reaching $212.34 by October 06, 2026, with a range of $204.29 to $218.68. 1-Year Outlook: Projected loss of -25.96%, with price at $111.47 by July 08, 2027, within a range of $105.60 to $116.43.

Key Takeaways

Becton, Dickinson and Company (NYSE:BDX) shares are flat 4.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Becton, Dickinson and Company trading at a premium to the broader market with a P/E of 38.18. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $246.65, suggesting 63.82% upside. Our AI forecast model points to short-term strength (8.65% over two weeks), a medium-term rise (41.03% over three months), and a longer-term loss (-25.96% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Becton, Dickinson and Company (BDX) stock price?
Becton, Dickinson and Company (NYSE: BDX) stock price is $149.42 in the last trading session. During the trading session, BDX stock reached the peak price of $155.98 while $148.23 was the lowest point it dropped to. The percentage change in BDX stock occurred in the recent session was -0.76% while the dollar amount for the price change in BDX stock was - $1.14.
BDX's industry and sector of operation?
The NYSE listed BDX is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Becton, Dickinson and Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BDX?
Ms. Elizabeth McCombs
Executive Vice President & Chief Technology Officer
Ms. Denise Fleming
Executive Vice President of Technology & Global Services and Chief Information Officer
Mr. Christopher J. DelOrefice
Executive Vice President & Chief Financial Officer
Ms. Shana Carol Neal
Executive Vice President & Chief People Officer
Ms. Francesca M. DeMartino
Senior Vice President & Head of Investor Relations
Michelle Quinn
Senior Vice President and Chief Ethics & Compliance Officer
Mr. Christopher DelOrefice
Executive Vice President & Chief Financial Officer
Mr. Thomas E. Polen Jr.
Pres, Chief Executive Officer & Chairman
Troy Kirkpatrick
Vice President of PR
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.
Senior Vice President, Chief Scientific Officer & Co-Chair of Scientific Advisory Board
Mr. David B. Hickey
Executive Vice President & Pres of Life Sciences Segment
Ms. Michelle Quinn
Executive Vice President & Gen. Counsel
Mr. Thomas J. Spoerel
Senior Vice President, Controller & Chief Accounting Officer
How BDX did perform over past 52-week?
BDX's closing price is 18.01% higher than its 52-week low of $127.59 where as its distance from 52-week high of $187.35 is -19.64%.
How many employees does BDX have?
Number of BDX employees currently stands at 70,000.
Link for BDX official website?
Official Website of BDX is: https://www.bd.com
How do I contact BDX?
BDX could be contacted at phone 201 847 6800 and can also be accessed through its website. BDX operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, United States.
How many shares of BDX are traded daily?
BDX stock volume for the day was 136.81K shares. The average number of BDX shares traded daily for last 3 months was 3M.
What is the market cap of BDX currently?
The market value of BDX currently stands at $54.13B with its latest stock price at $149.42 and 362.3M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph